Cargando…
Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal
BACKGROUND/PURPOSE: To search for a transmissible agent involved in lupus pathogenesis, we investigated the faecal microbiota of patients with systemic lupus erythematosus (SLE) for candidate pathobiont(s) and evaluated them for special relationships with host immunity. METHODS: In a cross-sectional...
Autores principales: | Azzouz, Doua, Omarbekova, Aidana, Heguy, Adriana, Schwudke, Dominik, Gisch, Nicolas, Rovin, Brad H, Caricchio, Roberto, Buyon, Jill P, Alekseyenko, Alexander V, Silverman, Gregg J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585303/ https://www.ncbi.nlm.nih.gov/pubmed/30782585 http://dx.doi.org/10.1136/annrheumdis-2018-214856 |
Ejemplares similares
-
Longitudinal gut microbiome analyses and blooms of pathogenic strains during lupus disease flares
por: Azzouz, Doua F, et al.
Publicado: (2023) -
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
por: Jayne, David, et al.
Publicado: (2022) -
A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis
por: Rovin, Brad H., et al.
Publicado: (2016) -
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
por: Furie, Richard A, et al.
Publicado: (2022) -
Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial
por: Jourde-Chiche, Noemie, et al.
Publicado: (2022)